Heregulin in breast cancer: Old story, new paradigm

Ashwani Khurana, Anatilde Gonzalez-Guerrico, Ruth Lupu

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Heregulin (HRG), a combinatorial ligand for the epidermal growth factor receptor family, is expressed in about 30% of breast cancer tumors. HRG induces tumorigenicity and metastasis of breast cancer cells and promotes hormone-independent growth [1]. Although HRG has been studied mostly in the context of the HRG receptor family, accumulating evidence suggests that HRG plays distinctive and causative roles in breast cancer tumorigenesis independent from the HRG receptors, demanding a comprehensive and independent study of HRG as a unique growth factor. This review provides a consolidated view of HRG and its biological role in the development, progression, and maintenance of breast cancer. Further, it provides further evidence that HRG is implicated in breast cancer resistance and targeting HRG may possibly be a beneficial tool to target a subgroup of breast carcinomas.

Original languageEnglish (US)
Pages (from-to)4874-4878
Number of pages5
JournalCurrent pharmaceutical design
Issue number30
StatePublished - Jan 1 2014


  • Breast cancer
  • Her3 receptor
  • Heregulin
  • Tumorigenicity

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Heregulin in breast cancer: Old story, new paradigm'. Together they form a unique fingerprint.

Cite this